HomeCompareRBCL vs KMB

RBCL vs KMB: Dividend Comparison 2026

RBCL yields 285714.29% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RBCL wins by $1.734986541242196e+31M in total portfolio value
10 years
RBCL
RBCL
● Live price
285714.29%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.734986541242196e+31M
Annual income
$17,337,928,197,276,910,000,000,000,000,000,000,000.00
Full RBCL calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.47
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,211.33
Full KMB calculator →

Portfolio growth — RBCL vs KMB

📍 RBCL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRBCLKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RBCL + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RBCL pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RBCL
Annual income on $10K today (after 15% tax)
$24,285,714.29/yr
After 10yr DRIP, annual income (after tax)
$14,737,238,967,685,373,000,000,000,000,000,000,000.00/yr
KMB
Annual income on $10K today (after 15% tax)
$445.84/yr
After 10yr DRIP, annual income (after tax)
$4,429.63/yr
At 15% tax rate, RBCL beats the other by $14,737,238,967,685,373,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RBCL + KMB for your $10,000?

RBCL: 50%KMB: 50%
100% KMB50/50100% RBCL
Portfolio after 10yr
$8.67493270621098e+30M
Annual income
$8,668,964,098,638,455,000,000,000,000,000,000,000.00/yr
Blended yield
99.93%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

RBCL
No analyst data
Altman Z
1.3
Piotroski
1/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.5% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RBCL buys
0
KMB buys
0
No recent congressional trades found for RBCL or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRBCLKMB
Forward yield285714.29%5.25%
Annual dividend / share$2.00$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17%
Portfolio after 10y$1.734986541242196e+31M$45.9K
Annual income after 10y$17,337,928,197,276,910,000,000,000,000,000,000,000.00$5,211.33
Total dividends collected$1.734908400352195e+31M$21.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: RBCL vs KMB ($10,000, DRIP)

YearRBCL PortfolioRBCL Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$28,582,129$28,571,428.57$11,314$613.68+$28.57MRBCL
2$76,351,353,429$76,320,770,551.21$12,865$759.19+$76351.34MRBCL
3$190,619,493,207,524$190,537,797,259,355.30$14,709$943.96+$190619493.19MRBCL
4$444,781,927,427,195,200$444,577,964,569,463,100.00$16,919$1,180.17+$444781927427.18MRBCL
5$969,967,353,346,567,200,000$969,491,436,684,220,000,000.00$19,588$1,484.33+$969967353346567.13MRBCL
6$1,976,961,629,315,093,000,000,000$1,975,923,764,247,012,300,000,000.00$22,838$1,879.06+$1976961629315092992.00MRBCL
7$3,765,923,944,594,039,000,000,000,000$3,763,808,595,650,671,000,000,000,000.00$26,832$2,395.60+$3.765923944594039e+21MRBCL
8$6,704,681,437,057,684,000,000,000,000,000$6,700,651,898,436,968,000,000,000,000,000.00$31,788$3,077.63+$6.704681437057683e+24MRBCL
9$11,156,275,836,497,016,000,000,000,000,000,000$11,149,101,827,359,364,000,000,000,000,000,000.00$38,000$3,986.82+$1.1156275836497015e+28MRBCL
10$17,349,865,412,421,960,000,000,000,000,000,000,000$17,337,928,197,276,910,000,000,000,000,000,000,000.00$45,872$5,211.33+$1.734986541242196e+31MRBCL

RBCL vs KMB: Complete Analysis 2026

RBCLStock

RBC Life Sciences, Inc. manufactures, markets, and distributes nutritional supplements and personal care products in North America, Southeast Asia, and Australia. The company's Nutritional Products segment offers nutritional supplements and personal care products, including herbs, vitamins, and minerals; and natural skin, hair, and body care products through a network of independent distributors and license arrangements. Its products include Stem-Kine, a dietary supplement; Microhydrin and Microhydrin Plus antioxidants; VitAloe, a blend of research-backed ingredients; OliViva, an antioxidant beverage to support immune and cardiovascular system; Organic Spirulina, a nutritious alga that provides range of nutrients and easily digested proteins; and NeuroBright to support brain function, and enhance energy and acuity. This segments products also comprise Colo-Vada Plus, a colon cleansing program; HydraCel to enhance the quality of drinking water; 24 Seven, a multivitamin/mineral supplement; Immune 360 to nourish and support the function of the immune system; and Aloe Gelee gel that provides the soothing and moisturizing. Its Medical Products segment offers wound care products for the treatment and healing of wounds, such as pressure ulcers, leg ulcers, cuts, burns, and abrasions. Its products include cleansers, dressings, hydrogels, collagen, calcium alginates, moisture barriers, antimicrobials, and a hydrogel wound dressing with Lidocaine. This segment also offers other wound care products designed to reduce destruction to skin and tissue caused by radiation; and to reduce pain and itching in the skin, and the internal mucosa caused by radiation reactions or reactions to various cancer medications. This segment sells its products under the MPM Medical brand to hospitals, nursing homes, clinics, and pharmacies through a network of medical/surgical supply dealers and pharmaceutical distributors. The company was founded in 1988 and is headquartered in Irving, Texas.

Full RBCL Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this RBCL vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RBCL vs SCHDRBCL vs JEPIRBCL vs ORBCL vs KORBCL vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.